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Purpose: Despite improved staging and operative techniques, 
rate of incomplete resection (R1) of NSCLC has remained 
significant over the last decades. Patients with R1 resection have 
significantly worse survival compared to those with complete 
resection (R0). SBRT delivers high dose radiotherapy (RT) to 
tumours, in a short time (1-10 treatments), with high precision 
while sparing normal organs. The efficacy of SBRT in treating 
small lung tumours is documented but its use as neo-adjuvant 
therapy in LA-NSCLC is not reported yet. We hypothesized that a 
short course of pre-operative SBRT can be done safely and could 
improve rates of R0 resection of LA-NSCLC and conducted a Phase 
I trial (LINNEARRE I) to investigate the safety and feasibility of 
delivering, timely, neo-adjuvant SBRT in operable patients with 
LA-NSCLC at risk for positive resection margins. 
Methods and Materials: Twenty appropriately staged (PET-
CT/MRI and mediastinal staging) patients with biopsy proven T3-
T4, N0-1, M0 NSCLC will be enrolled. Patients would be deemed 
medically operable by the surgical team but at risk of < R0 
resection (due to invasion of mediastinal or hilar structures, 
chest wall or vertebral bodies). Primary outcome is feasibility 
i.e. the ability to complete SBRT as planned and proceed to 
surgery (Sx) within six weeks. Secondary outcomes include acute 
and late adverse events, R0/R1/R2 rates and secondary 
surrogates of feasibility. SBRT is delivered in over two weeks (in 
10 fractions). Dose is escalated from 35 Gy to 50 Gy. Five patients 
will be accrued to each dose level of 35, 40, 45 and 50 Gy. At the 
latter dose level, normal tissue (nt) BED (133 Gy) exceeds that 
delivered concurrently with chemotherapy with 63-66 Gy/30 
fractions (107-110 Gy) but is similar to that delivered by recent 
dose-escalation chemo-RT (74 Gy) studies. Clinical target volume 
(CTV) includes only the area of tumour deemed at risk of 
incomplete resection expanded by 3-5 mm into surrounding 
tissues where there is clinical suspicion of invasion.  
Results: This study opened to accrual in late 2015. Dosimetric 
feasibility was tested in virtual plans of selected eligible cases 
that were planned to receive treatment at the highest planned 
dose level (50 Gy). All cases met dosimetric constraints for 
planned target volume (PTV) and organs at risk (OAR: great 
vessels, heart, esophagus, and proximal bronchi). Examples of 
virtual plans will be illustrated. 
Conclusions: This is the first study to investigate SBRT as a neo-
adjuvant therapy in LA-NSCLC. Virtual plans suggest that is 
feasible to deliver neoadjuvant SBRT safely to tumour volumes 
at risk for positive margins. A key aims of this study is to examine 
the adaptation of workflow in a Canadian academic institution 
to achieve timely neoadjuvant SBRT delivery. If successful this 
Phase I study will lead to further evaluation of pre-operative 
SBRT in LA-NSCLC, to help achieve improved rates of complete 
resection and improved outcomes. 
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Purpose: Chest wall (CW) toxicity (rib fracture and/or pain) is a 
well-known complication after stereotactic body radiotherapy 
(SBRT) for early-stage lung cancer. The aim of this study is to 
evaluate the frequency of CW toxicity following SBRT and to 
determine the dosimetric parameters that influence the risk of 
CW toxicity. 
Methods and Materials: We reviewed medical charts and 
radiotherapy (RT) plans from patients treated for T1 or T2N0 
peripheral primary lung cancer between 2009 and 2015. 
Treatment was delivered by Cyberknife®, helical tomotherapy 
or using volumetric modulated arc therapy. CW structure 
corresponded to a 3 cm expansion of the lung excluding the lung 
volume. The median total dose delivered to the planning target 
volume was 60 Gy (range, 54- 60). SBRT was delivered in 3 
fractions for patients with a CW V30 of less than 30cc. If the CW 
V30 exceeded 30cc, 5 fractions were delivered and the SBRT plan 
was optimized on the biologically equivalent parameter of CW 
V30: CW V37 < 30 cc. We studied the association between CW 
toxicity and delivered dose using the Student T-test. 
Results: Three hundred and eighty-one lesions were treated in a 
cohort of 363 patients with a median follow up of 17 months 
(range, 1 - 62). Twenty patients (6 %) had CW toxicity: 13 
patients (4%) developed CW pain and nine patients (3%) 
developed rib fractures. For patient treated in 3 fractions, the 
mean CW V30 was 21 cc for patients with CW toxicity and 16 cc 
for patients without toxicity (p < 0.05). For patients treated in 5 
fractions (n = 55), the small number of patients with chest wall 
toxicity did not allow comparison of V37 between groups. The 
CW V37 was inferior to 30 cc for all patients. CW toxicity rates 
were similar in the 3 or 5 fractions group (6% versus 4%). The 
two-year local control was similar in the two groups (96% versus 
94%). 
Conclusions: This study confirms that CW V30 is significantly 
associated with CW toxicity. When the CW V30 is greater than 30 
cc, delivering SBRT in 5 fractions and with a CW V37 of less than 
30 cc can limit CW toxicity without compromising tumour 
control. 
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Purpose: Surgery remains the standard treatment for medically 
operable patients with early-stage non-small cell lung carcinoma 
(NSCLC). Adjuvant chemotherapy is routinely recommended 
following resection of tumours > 4 cm. For patients who decline 
surgery or are medically unfit, stereotactic body radiation 
therapy (SBRT) has emerged as an excellent alternative. The 
benefit of adjuvant chemotherapy following lung SBRT has not 
been studied. To evaluate the potential benefit of such a 
treatment, we reviewed the outcomes of T2N0 patients treated 
with SBRT. 
Methods and Materials: We reviewed patients treated with SBRT 
for primary early-stage NSCLC between 2009 and 2015. Total 
target doses were between 50 and 60 Gy, administered in 3 – 8 
fractions. All patients had a staging FDG PET/CT and histologic 
confirmation was obtained whenever possible (70 %). Mediastinal 
staging (MS) was performed if lymph node involvement was 
suspected on CT or PET/CT. Survival outcomes were estimated 
using the Kaplan-Meier method. 
Results: Among the 556 NSCLC early stage patients treated with 
SBRT, 115 patients were staged T2N0. In T2N0 patients, the mean 
lesion size was 3.4 cm (range, 3 - 4.6cm). The one-year and 
three-year overall survival were 88% and 68% for patients with 
T2 disease, compare to 95% and 80% for the T1N0 patients (p < 
0.05). The median disease-free survival was higher in the T1N0 
group (48 versus 32 months). For T2N0 patients, the one-year and 
three-year local control rates were 98% and 91% respectively. 
Twenty patients (16.5%) presented a relapse, amongst which 16 
(80%) were nodal or distant. The median survival of T2N0 patient 
post-relapse was 20 months. 
Conclusions: Lung SBRT provided high local control rates, even 
for larger tumours. Overall survival and patterns of failure are 
similar to surgery. It remains to be seen if SBRT patients will be 
fit for and accepting of adjuvant chemotherapy but these results 
raise the question if adjuvant treatment is advisable post SBRT. 
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